XBiotech Inc. XBIT
1.95 USD -0.02 (-1.02%)
At closeNov 11, 2026, 4:00 PM EST
1.95 0.00 0.00%
After hours · Nov 11, 4:00 PM ET
1.95 Day range 1.98
1.80 52-week range 3.06
- YTD
- -18.41%
- 1 year
- -33.67%
News
benzinga.com XBiotech Appoints Jan-Paul Simard Co-CEO, Effective Oct. 23 XBiotech Inc. (NASDAQ: XBIT) today announced that its Board of Directors have elected Jan-Paul Simard to serve as Co-Chief Executive Officer alongside CEO Dr. Sushma Shivaswamy, effective Oct. 23,…
benzinga.com XBiotech Announces Data From Its Phase II Portion Of Multicenter TASKIN Clinical Study Meets Pre-Specifed Primary Efficacy Success Criterion Under Simon Two-Stage Design; 61.3% Participants In Vilamakitug Experimental Arm Were Alive, Surpassing Threshold Of 42, More Surviving Patients XBiotech Inc. (NASDAQ: XBIT) today announced positive final efficacy results from the randomized Phase II portion of the multicenter TASKIN clinical trial. The investigator-sponsored study—funded by…- benzinga.com XBiotech Says IND Application For V-SPINE Study Completes 30-Day FDA Review Without Clinical Hold, Clearing Path For U.S. Patient Enrollment XBiotech Inc. (NASDAQ:XBIT) today announced that its Investigational New Drug (IND) application for V-SPINE (PT064), a Phase II, double-blind, placebo-controlled, randomized study evaluating the…
benzinga.com XBiotech Q1 EPS $(0.18) Up From $(0.36) YoY XBiotech (NASDAQ:XBIT) reported quarterly losses of $(0.18) per share. This is a 50 percent increase over losses of $(0.36) per share from the same period last year.
benzinga.com XBiotech Announces John Simard To Retire As CEO, To Continue As Chairman; Sushma Shivaswamy Appointed Interim CEO Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. XBiotech, Inc. ("XBiotech" or the "Company")…- benzinga.com XBiotech Q3 EPS $(0.20) Down From $(0.16) YoY XBiotech (NASDAQ:XBIT) reported quarterly losses of $(0.20) per share. This is a 25 percent decrease over losses of $(0.16) per share from the same period last year.
benzinga.com XBiotech Q2 EPS $(0.06) Up From $(0.43) YoY XBiotech (NASDAQ:XBIT) reported quarterly losses of $(0.06) per share. This is a 86.05 percent increase over losses of $(0.43) per share from the same period last year.- benzinga.com What's Going On With Small-Cap Cancer Focused XBiotech On Tuesday? XBiotech reveals results from its Phase 1/Phase 2 1-BETTER Study for advanced pancreatic cancer, highlighting the safety and tolerability of Natrunix with the ONIVYDE + 5-Fluorouracil + Leucovorin…
- benzinga.com XBiotech Shares Results From Randomized Double-Blinded Phase 1/2 Study Suggest Potential Breakthrough Treatment For Advanced Pancreatic Cancer XBiotech (NASDAQ:XBIT) announced today data from its Phase 1/Phase 2 randomized, double-blind, placebo-controlled multi-center study for advanced pancreatic cancer. Known as 1-BETTER, the study…
- benzinga.com 12 Health Care Stocks Moving In Monday's Pre-Market Session
benzinga.com XBiotech Announces Enrollment Completion Of Phase I Clinical Trial For Hutrukin, A Novel Candidate Therapy For Stroke XBiotech Inc. (NASDAQ:XBIT) Announces that Hutrukin is being developed by XBiotech as a breakthrough therapy to reduce brain injury after stroke. The last subject in a randomized, open-label,…
benzinga.com 12 Health Care Stocks Moving In Tuesday's After-Market Session - benzinga.com XBiotech Announces Enrollment Completion Of Phase II, Placebo Controlled, Multicenter Study For Natrunix In Pancreatic Cancer XBiotech Inc. announced today completion of enrollment of the Phase II portion of its 1-BETTER study—a Phase I/II randomized, double-blind, placebo-controlled clinical study for Natrunix in…
- benzinga.com XBiotech Announces First Patient Begins Novel Natrunix Therapy In Phase II Rheumatoid Arthritis Clinical Trial XBiotech Inc. (NASDAQ:XBIT) today began treating the first patient in a phase II, double-blind, placebo-controlled, randomized clinical study to evaluate Natrunix as a new treatment for Arthritis.…
- benzinga.com Why Doximity Shares Are Trading Lower By 8%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session Gainers
- benzinga.com Dow Jumps Over 100 Points; US Housing Starts Rise In April U.S. stocks traded higher this morning, with the Dow Jones gaining more than 100 points on Wednesday. Following the market opening Wednesday, the Dow traded up 0.37% to 33,135.37 while the NASDAQ…
- benzinga.com XBiotech Announces First Subject Enrollment In Phase I Clinical Trial For Hutrukin, A Novel Candidate Therapy For Stroke XBiotech Inc. (NASDAQ:XBIT) has enrolled the first subject in a randomized, open-label, placebo-controlled dose escalation clinical study to evaluate safety and pharmacokinetics of Hutrukin. Hutrukin…
- benzinga.com Stocks That Hit 52-Week Lows On Monday On Monday, 79 companies reached new 52-week lows.
- benzinga.com Stocks That Hit 52-Week Lows On Thursday Thursday saw 177 companies set new 52-week lows.
benzinga.com XBiotech Announces First Patient Enrolled Into The French National Cancer Institute Sponsored Phase I/II/III Clinical Study For Natrunix Therapy For Colorectal Cancer XBiotech (NASDAQ:XBIT) announced today the enrollment of the first patient in a multicenter, randomized clinical study for Natrunix in combination with trifluridine/tipiracil for the treatment of…
benzinga.com Stocks That Hit 52-Week Lows On Thursday On Thursday, 1076 companies hit new 52-week lows.- benzinga.com Stocks That Hit 52-Week Lows On Tuesday On Tuesday, 507 stocks hit new 52-week lows.
- benzinga.com Stocks That Hit 52-Week Lows On Monday On Monday, 429 stocks made new 52-week lows.
- benzinga.com Stocks That Hit 52-Week Lows On Wednesday On Wednesday, 238 companies achieved new lows for the year.
- benzinga.com Stocks That Hit 52-Week Lows On Monday On Monday, 273 companies set new 52-week lows.
- benzinga.com Stocks That Hit 52-Week Lows On Monday On Monday, 195 stocks hit new 52-week lows.
benzinga.com Stocks That Hit 52-Week Lows On Friday On Friday, 109 stocks hit new 52-week lows.- benzinga.com Stocks That Hit 52-Week Lows On Monday On Monday, 92 companies set new 52-week lows.
- benzinga.com Stocks That Hit 52-Week Lows On Thursday On Thursday, 550 companies achieved new lows for the year.
- benzinga.com Stocks That Hit 52-Week Lows On Thursday During the Thursday's session, 100 stocks hit new 52-week lows.
- benzinga.com Stocks That Hit 52-Week Lows On Tuesday On Tuesday, 540 companies set new 52-week lows.
- benzinga.com Stocks That Hit 52-Week Lows On Monday On Monday, 198 companies reached new 52-week lows.
- benzinga.com 74 Biggest Movers From Yesterday Gainers T Stamp Inc. (NASDAQ: IDAI) shares surged 123.8% to close at $4.70 on Thursday. Trust Stamp reported the launch of its Biometric Multi-Factor Authentication (Biometric MFATM) solution.
- benzinga.com Stocks That Hit 52-Week Lows On Tuesday During Tuesday, 581 stocks hit new 52-week lows. Interesting Highlights From Today's 52-Week Lows Meta Platforms (NASDAQ:FB) was the biggest company on a market cap basis to set a new 52-week low.
- benzinga.com Stocks That Hit 52-Week Lows On Monday On Monday, 721 companies achieved new lows for the year.
- benzinga.com Stocks That Hit 52-Week Lows On Thursday On Thursday, 236 companies hit new 52-week lows.
- benzinga.com Stocks That Hit 52-Week Lows On Monday On Monday, 466 companies hit new 52-week lows.
- benzinga.com Stocks That Hit 52-Week Lows On Monday On Monday, 671 companies achieved new lows for the year.
- benzinga.com Stocks That Hit 52-Week Lows On Thursday During Thursday, 166 stocks hit new 52-week lows.
- benzinga.com The Daily Biotech Pulse: ASH Meeting Wraps, Fast Track Designation For Equillium, Pfizer To Buy $3M In ContraFect Shares
- benzinga.com 80 Biggest Movers From Yesterday
- benzinga.com Mid-Afternoon Market Update: Dow Falls 90 Points; XBiotech Shares Spike Higher
- benzinga.com 48 Stocks Moving In Monday's Mid-Day Session
- benzinga.com Mid-Day Market Update: Synthorx Jumps Following Acquisition News; Biocept Shares Plunge
- benzinga.com Mid-Morning Market Update: Markets Mixed; Merck To Acquire ArQule For $20/Share
- benzinga.com 38 Healthcare Stocks Moving In Monday's Pre-Market Session
- benzinga.com 20 Stocks Moving In Monday's Pre-Market Session
- benzinga.com 7 Stocks To Watch For December 9, 2019
- benzinga.com Stocks That Hit 52-Week Highs On Wednesday
- benzinga.com Stocks That Hit 52-Week Highs On Tuesday